Autolus Therapeutics (AUTL) Free Cash Flow (2017 - 2025)

Autolus Therapeutics' Free Cash Flow history spans 6 years, with the latest figure at -$48.6 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 68.81% year-over-year to -$48.6 million; the TTM value through Dec 2025 reached -$284.7 million, down 36.85%, while the annual FY2025 figure was -$284.7 million, 36.85% down from the prior year.
  • Free Cash Flow reached -$48.6 million in Q4 2025 per AUTL's latest filing, up from -$72.3 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$24.2 million in Q4 2022 to a low of -$86.3 million in Q3 2024.
  • Average Free Cash Flow over 4 years is -$51.8 million, with a median of -$47.4 million recorded in 2023.
  • The largest YoY upside for Free Cash Flow was 16.24% in 2025 against a maximum downside of 104.07% in 2025.
  • A 4-year view of Free Cash Flow shows it stood at -$24.2 million in 2022, then fell by 8.77% to -$26.3 million in 2023, then fell by 9.33% to -$28.8 million in 2024, then crashed by 68.81% to -$48.6 million in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Free Cash Flow are -$48.6 million (Q4 2025), -$72.3 million (Q3 2025), and -$80.1 million (Q2 2025).